Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

The FDA approval clears the path for a U.S. launch in January 2026. ・Trial and expanded access data showed strong response rates and short-term survival in high-risk patients. ・Yartemlea becomes the ...

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Crystal precipitation from aqueous solution occurs through multiple pathways. Besides the classical ion -byion addition, non-classical crystallization mechanisms, such as multi-ion polymer and ...

The following is a summary of “Prognostic role of activation of the complement pathways in the progression of advanced IgA nephropathy to end-stage renal disease,” published in the October 2024 issue ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-blind ...